Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04221438 · ClinicalTrials.gov registry record · Phase 2
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
A Phase 2 study, sponsored by ECOG-ACRIN Cancer Research Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT04221438 is a Phase 2 study that was terminated before completion, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 3 participants.
The verdict
NCT04221438, a Phase 2 study, was terminated before completion, sponsored by ECOG-ACRIN Cancer Research Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase II trial studies how well encorafenib and binimetinib work before surgery in treating patients with BRAF V600-mutated stage IIIB-D melanoma that has spread to the lymph nodes. Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This trial also studies how well 18F-FLT positron emission tomography (PET)/computed tomography (CT) works in predicting the response of melanoma to encorafenib and binimetinib. 18F-FLT is an imaging agent, sometimes called a tracer. PET and CT are types of imaging scans. Using 18F-FLT PET/CT together with encorafenib and binimetinib may provide more information on melanoma over time.
Interventions
- PROCEDURE Conventional Surgery
- DRUG Binimetinib
- DRUG Encorafenib
- OTHER Fluorothymidine F-18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-09-22 |
| Est. Completion | 2025-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04221438
The ClinicalTrials.gov registry entry for NCT04221438 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Conventional Surgery is the first listed.
NCT04221438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04221438 about?
NCT04221438 is a clinical study titled "Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement". This phase II trial studies how well encorafenib and binimetinib work before surgery in treating patients with BRAF V600-mutated stage IIIB-D melanoma that has spread to the lymph nodes. Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell gr...
What is the current status of trial NCT04221438?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2021-09-22. Estimated completion is 2025-01-31.
What interventions are being tested in trial NCT04221438?
The interventions under investigation include: Conventional Surgery (PROCEDURE), Binimetinib (DRUG), Encorafenib (DRUG), Fluorothymidine F-18 (OTHER).
Who is sponsoring clinical trial NCT04221438?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.